Disitamab Vedotin + Toripalimab for HER2 Advanced Urothelial Cancer
Ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
Table of Contents
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events – including heart attack, stroke, and cardiovascular death – in adults with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo. the trial involved over 17,600 participants across 30 countries and followed them for an average of 3.4 years. While semaglutide demonstrated meaningful weight loss,the cardiovascular safety signal is prompting a reassessment of its use in this specific patient population.
The Data: Key findings from the SELECT Trial
The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group. This translates to a hazard ratio of 1.33, indicating a 33% increased risk. Importantly, the weight loss achieved with semaglutide – an average of approximately 15% of initial body weight – did not appear to offset this cardiovascular risk. The findings were presented at the European Congress on Obesity and concurrently published online.
| Outcome | Semaglutide Group (%) | Placebo Group (%) | Hazard Ratio |
|---|---|---|---|
| MACE (Heart Attack, Stroke, Cardiovascular Death) | 6.5 | 4.9 | 1.33 |
| cardiovascular Death | 3.0 | 2.2 | 1.35 |
| Non-Fatal Stroke | 1.7 | 1.3 | 1.31 |
| non-Fatal Heart Attack | 2.5 | 1.9 | 1.31 |
Who is affected? Understanding Patient Risk Profiles
These findings primarily impact individuals with obesity *and* pre-existing cardiovascular disease. This includes those with a history of heart attack, stroke, peripheral artery disease, or other established cardiovascular conditions. The trial did *not* include patients with type 2 diabetes,raising questions about whether the cardiovascular risk profile differs in that population. Individuals without pre-existing heart disease likely face a different risk-benefit calculation.
it’s crucial to differentiate between correlation and causation. While the SELECT trial demonstrates an association between semaglutide and increased cardiovascular events, it doesn’t definitively prove that the drug *caused* these events. Other factors, such as underlying health conditions and lifestyle choices, could contribute.
Why Does This matter? The Shifting Landscape of Obesity Treatment
Semaglutide, initially approved for type 2 diabetes, gained widespread popularity for its dramatic weight loss effects. It was frequently enough touted as a potential breakthrough in obesity treatment,with some even suggesting cardio-protective benefits. The SELECT trial challenges this narrative, highlighting the importance of a nuanced approach to prescribing these medications. The results underscore the need for careful patient selection and ongoing monitoring for cardiovascular events.